The publicly listed company Prenetics will obtain more funds by selling its subsidiary ACT Genomics to explore Bitcoin reserve strategies.

PANews June 18 news, according to an official announcement, consumer health science company Prenetics (NASDAQ: PRE) has reached a final agreement to transfer its ownership of genomic medicine business ACT Genomics Holdings to Delta Electronics (TWSE: 2308). The total transaction value is up to $71.78 million, and Prenetics expects to receive approximately $46 million in cash. After the transaction is completed, the company’s cash reserves will increase to $86 million, with short-term assets reaching $117 million, while maintaining a zero-debt status. CEO Danny Yeung stated that the ample cash reserves will enable the company to explore innovative financial strategies such as digital asset and Bitcoin treasury management.